Gene therapy studies from our laboratory demonstrated that PGC1α gene delivery using lentiviral vectors in the APP23 model of amyloidosis (overexpressing APP with the Swedish mutation) at pre-symptomatic stages of AD resulted in decreased Aβ plaques, neuronal loss, and improved memory [38]. This evidence concerns the gene PPARGC1A and amyloidosis.